Alma Habib, MD, The Ohio State University Comprehensive Cancer Center, talks about the fact that disparities are able to be recognized in leukemia/lymphoma care, but the questions of how to address these disparities remain.
Addressing disparities in leukemia/lymphoma care is a next step since multiple disparities have already been identified, discusses Alma Habib, MD, hematology medical oncology fellow at The Ohio State University.
Transcript
How are disparities in leukemia/lymphoma treatment being addressed in the current treatment landscape?
I think over the past few years, we've really done a good job of identifying disparities in our research. We've uncovered disparities in cancer care related to aging, gender, socioeconomic status, insurance status, and even through DNA sequencing. We've also uncovered that every individual has a different type of cancer, especially patients from minority racial groups. Their cancer may look different. Black patient cancers may look different from White patient cancers. I think we've really done a good job about uncovering these disparities and differences in cancer. For example, in acute myeloid leukemia, we know that Black patients have more mutations that are considered less favorable than White patients. This really impacts the way we treat their disease and their survival rates.
But I think the most important question to ask now that we've uncovered disparities is, what do we do about them? And what can we do as a health care team to improve outcomes for patients? The answers to these questions are largely going to be based on the patient. Every individual patient has different barriers to their treatment, to their access. I think a lot of our efforts now need to be focusing on that. How can we overcome the barriers that patients face in order for them to get the best care possible? And how can we improve access to clinical trials and these new treatments that we've developed?
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Health Equity, Accessibility Essential to Supporting Women Affected by Hemophilia
May 10th 2024Due to often being overlooked as only carriers of hemophilia, the review authors sought to highlight the needs of female caretakers for patients with the disorder and the possibility of women themselves being affected by it.
Read More